Inotiv

Global Pharma And Biotech R&D Increase Will Build Value

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

06 Apr 25

Updated

05 Dec 25

n/a

AnalystConsensusTarget's Fair Value

n/a

-87.2%

-5.4%

-87.2%

-5.4%

You can edit this narrative until Dec 6 2:05 AM. Then, changes will post as Updates.

Author's Valuation

US$4.8384.2% undervalued

AnalystConsensusTarget Fair Value

Narrative

Updates5

Shared on 05 Dec 25

Fair value Decreased 12%

NOTV: Future Margins And Legal Settlement Will Support Share Upside

Narrative Update on Inotiv Analysts have lowered their average price target on Inotiv by roughly 12 percent, to about $4.83 per share from around $5.50. They cite slightly softer revenue growth assumptions that are only partly offset by expectations for improved profit margins and a lower future earnings multiple.

Shared on 01 May 25

Fair value Increased 1.29%

Shared on 24 Apr 25

Fair value Decreased 11%

AnalystConsensusTarget has decreased future PE multiple from 4.7x to 4.2x.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Increased 10%

AnalystConsensusTarget has increased future PE multiple from 4.0x to 4.7x and decreased shares outstanding growth rate from 0.3% to 0.1%.

AnalystConsensusTarget Fair Value

US$4.83

84.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

5.29%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

12.50%

Calculation

US$92.68m

Earnings '28

2.60x

PE Ratio '28

US$240.86m

Market Cap '28

US$240.86m

Market Cap '28

35.86m

No. shares '28

US$6.72

Share Price '28

US$6.72 Share Price '28

Discounted to 2025 @ 12.50% p.a.

US$4.72

Fair Value '25